Your browser doesn't support javascript.
loading
Real-World Treatment Patterns, Health Outcomes, and Healthcare Resource Use in Advanced Common EGFR-Positive Non-Small Cell Lung Cancer Patients Treated with Osimertinib in Alberta.
Cheung, Winson Y; Carbonell, Chantelle; Navani, Vishal; Sangha, Randeep S; Ewara, Emmanuel M; Elia-Pacitti, Julia; Iczkovitz, Sandra; Jarada, Tamer N; Warkentin, Matthew T.
Afiliación
  • Cheung WY; Department of Oncology, Cumming School of Medicine, University of Calgary, Calgary, AB T2N 1N4, Canada.
  • Carbonell C; Department of Oncology, Cumming School of Medicine, University of Calgary, Calgary, AB T2N 1N4, Canada.
  • Navani V; Department of Oncology, Cumming School of Medicine, University of Calgary, Calgary, AB T2N 1N4, Canada.
  • Sangha RS; Department of Oncology, Faculty of Medicine & Dentistry, University of Alberta, Edmonton, AB T6G 2R3, Canada.
  • Ewara EM; Johnson & Johnson Innovative Medicine, Toronto, ON M3C 1L9, Canada.
  • Elia-Pacitti J; Johnson & Johnson Innovative Medicine, Toronto, ON M3C 1L9, Canada.
  • Iczkovitz S; Johnson & Johnson Innovative Medicine, Toronto, ON M3C 1L9, Canada.
  • Jarada TN; Department of Oncology, Cumming School of Medicine, University of Calgary, Calgary, AB T2N 1N4, Canada.
  • Warkentin MT; Department of Oncology, Cumming School of Medicine, University of Calgary, Calgary, AB T2N 1N4, Canada.
Curr Oncol ; 31(8): 4382-4396, 2024 Jul 31.
Article en En | MEDLINE | ID: mdl-39195310
ABSTRACT
There is limited information on the treatment trajectory and outcomes of patients with advanced cEGFRm NSCLC treated with osimertinib in routine clinical practice in Canada. By using and analyzing population-based administrative data and detailed chart abstraction in the province of Alberta, our objective was to capture Canadian-specific real-world treatment patterns, health outcomes, and healthcare resource utilization (HCRU) in advanced cEGFRm NSCLC patients who were (a) treated with osimertinib and (b) those receiving treatment after osimertinib. In our study cohort, we found that the overall survival rates for real-world patients receiving osimertinib were less favorable than those observed in clinical trials (24.0 versus 38.6 months). The attrition rate after osimertinib was substantial and high HCRU persisted across many years after diagnosis and treatment. This study provides important real-world evidence on contemporary survival, treatment patterns, and healthcare use among cEGFRm NSCLC patients treated with osimertinib and suggests that further research efforts are needed to improve therapeutic options in both the first and subsequent line settings.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Acrilamidas / Carcinoma de Pulmón de Células no Pequeñas / Receptores ErbB / Compuestos de Anilina / Neoplasias Pulmonares Límite: Aged / Aged80 / Female / Humans / Male / Middle aged País/Región como asunto: America do norte Idioma: En Revista: Curr Oncol Año: 2024 Tipo del documento: Article País de afiliación: Canadá Pais de publicación: Suiza
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Acrilamidas / Carcinoma de Pulmón de Células no Pequeñas / Receptores ErbB / Compuestos de Anilina / Neoplasias Pulmonares Límite: Aged / Aged80 / Female / Humans / Male / Middle aged País/Región como asunto: America do norte Idioma: En Revista: Curr Oncol Año: 2024 Tipo del documento: Article País de afiliación: Canadá Pais de publicación: Suiza